Compare Ascendis Pharma A/S (ASND) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Howmet Aerospace Inc — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Howmet Aerospace Inc trades at $271 (market cap $108.37B). The key difference: Howmet Aerospace Inc is far larger — about 6.1× Ascendis Pharma A/S's market cap, and Howmet Aerospace Inc pays a 0.18% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HWM | |
|---|---|---|
Market Cap | $17.74B | $108.37B |
Sector | Health | Industrials |
52-Week High | $277.18 | $283.23 |
52-Week Low | $163.32 | $171.00 |
Enterprise Value | $18.11B | $110.62B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Howmet Aerospace (HWM) trades at $270.85, down 1.07% on the day, with a bullish technical outlook supported by moving averages and key support at $268. The company reported strong profitability with a 20.22% net margin and ROE of 33.98%, though Q1 2026 earnings missed expectations. Recent news highlights growth in commercial aerospace and defense sectors, with Q2 2026 results due August 6, 2026.
HWM's premium valuation (P/E 62.84) reflects growth optimism, but execution risks and earnings volatility pose challenges. Analyst consensus is bullish with a $317.29 price target, suggesting 17% upside. Investors should weigh robust cash flow and sector tailwinds against high multiples and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
